RJV.F SomnoMed Limited
- Market cap
- EUR 42.2M
- P/E
- -
- P/B
- 1.40x
- ROE
- -5.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is RJV.F undervalued?
Graham numberThe Graham number of SomnoMed Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SomnoMed Limited fundamental analysis
No fundamental analysis for SomnoMed Limited yet.
SomnoMed Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SomnoMed Limited
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. The company offers SomnoDent, such as SomnoDent Avant, SomnoDent Classic, SomnoDent Flex, herbst advance, and SomnoDent Fusion for the treatment of obstructive sleep apnea. It also provides SomMorning Repositioner, a product designed to help return patient's mandible back to its pre-treatment cent…
Full company profileSomnoMed Limited financial statements
SomnoMed Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 49.3M | 63.6M | 58.9M | 57.3M | 62.7M | 72.6M | 83.6M | 91.7M | 115M |
| Gross Profit | 28.8M | 38.2M | 34.6M | 33.1M | 37.7M | 44.3M | 51.9M | 55.1M | 70.0M |
| Operating Income | -3.73M | -8.87M | 918K | -941K | -855K | -4.13M | -4.07M | -8.33M | 976K |
| EBITDA | -2.51M | -7.22M | 2.26M | 4.00M | 3.24M | 525K | 376K | -2.63M | 5.09M |
| Net Income | -3.34M | -8.62M | -16.4M | -1.12M | -1.19M | -4.44M | -8.00M | -12.2M | -2.65M |
| EPS | -0.05 | -0.13 | -0.24 | -0.01 | -0.02 | -0.06 | -0.10 | -0.06 | -0.01 |
| Balance Sheet | |||||||||
| Total Assets | 41.2M | 45.7M | 34.8M | 61.7M | 56.2M | 58.1M | 62.5M | 69.8M | 75.0M |
| Total Liabilities | 10.3M | 12.9M | 16.9M | 27.9M | 24.0M | 30.3M | 40.1M | 24.8M | 27.6M |
| Shareholders' Equity | 32.2M | 36.1M | 17.8M | 33.8M | 32.2M | 27.8M | 22.4M | 45.0M | 47.4M |
| Cash & Short-term Investments | 14.2M | 13.4M | 7.70M | 30.2M | 21.1M | 15.6M | 12.0M | 16.2M | 17.2M |
| Cash Flow | |||||||||
| Operating Cash Flow | -2.68M | -9.47M | -6.55M | 5.19M | 2.71M | 1.86M | -3.88M | - | - |
| Capital Expenditure | 2.39M | 2.01M | 1.34M | 1.76M | 2.15M | 1.01M | 3.14M | 5.34M | 5.74M |
| Free Cash Flow | -5.31M | -11.6M | -8.21M | 3.00M | -1.43M | -6.93M | -10.3M | -11.7M | 2.54M |
| Ratios | |||||||||
| ROE | -10.4% | -23.9% | -92.2% | -3.3% | -3.7% | -16.0% | -35.7% | -27.2% | -5.6% |
| ROA | -8.1% | -18.9% | -47.3% | -1.8% | -2.1% | -7.6% | -12.8% | -17.5% | -3.5% |
| Net Profit Margin | -6.8% | -13.6% | -27.9% | -2.0% | -1.9% | -6.1% | -9.6% | -13.4% | -2.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SomnoMed Limited dividends
SomnoMed Limited has not paid dividends in the last 10 fiscal years.
Who owns SomnoMed Limited
- Insiders 26.01%
- Institutions 63.37%
- Public & others 10.62%
- Shares outstanding 220M
- Free float 101M
SomnoMed Limited company profile
- Company name
- SomnoMed Limited
- Ticker
- RJV.F
- ISIN
- AU000000SOM1
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- June
- Address
- 20 Clarke Street, Crows Nest, NSW, Australia, 2065
- Phone
- 61 2 9467 0400
- Website
- somnomed.com/au
About SomnoMed Limited
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. The company offers SomnoDent, such as SomnoDent Avant, SomnoDent Classic, SomnoDent Flex, herbst advance, and SomnoDent Fusion for the treatment of obstructive sleep apnea. It also provides SomMorning Repositioner, a product designed to help return patient's mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient's upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances. SomnoMed Limited was incorporated in 1987 and is headquartered in Crows Nest, Australia.
SomnoMed Limited management
10- Ms. Karen Borg B.A.CEO & Executive Director
- Ms. Ye-Fei GuoChief Financial Officer
- Mr. Greg KnightChief Operating Officer
- Mr. David LewisChief Information Officer
- Mr. Nathan MinnichChief Marketing Officer
- Ms. Janice Hiskett-JonesChief People Officer
- Mr. Marco Van KleefPresident of Europe
- Mr. Keshan GunasingheChief Product Officer
- Mr. Terence A. Flitcroft B.Com., B.Comm., C.A., SF FINCompany Secretary · born 1959
- Mr. Christopher BedfordVice President of Global Production and Product Development